Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

531 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Sota J, Vannozzi L, di Scala G, Guerriero S, Orlando I, Franceschini R, Capozzoli M, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: iannone f. Clin Rheumatol. 2018 Jun;37(6):1715-1720. doi: 10.1007/s10067-018-4092-4. Epub 2018 Apr 18. Clin Rheumatol. 2018. PMID: 29671190
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G; GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Iannone F, et al. Ann Rheum Dis. 2007 Feb;66(2):249-52. doi: 10.1136/ard.2006.058776. Epub 2006 Jul 12. Ann Rheum Dis. 2007. PMID: 16837489 Free PMC article.
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G; Gruppo Italiano di Studio sulle Early Arthritides (GISEA). Iannone F, et al. J Rheumatol. 2012 Jun;39(6):1179-84. doi: 10.3899/jrheum.111125. Epub 2012 Apr 1. J Rheumatol. 2012. PMID: 22467933
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G. Atzeni F, et al. Among authors: iannone f. Autoimmun Rev. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13. Autoimmun Rev. 2012. PMID: 22796281
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.
Iannone F, Gremese E, Gallo G, Sarzi-Puttini P, Botsios C, Trotta F, Gasperini S, Galeazzi M, Adami S, Cantini F, Sebastiani M, Gorla R, Marchesoni A, Giardina A, Foti R, Mele A, Bruschi E, Bagnato G, Erre GL, Lapadula G; GISEA (Gruppo Italiano Studio Early Arthritis). Iannone F, et al. Clin Rheumatol. 2014 Jan;33(1):31-7. doi: 10.1007/s10067-013-2348-6. Epub 2013 Aug 18. Clin Rheumatol. 2014. PMID: 23954923
531 results